Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV Genotype: FDA's Evaluation
Hepatology - United States
doi 10.1002/hep.29601
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2018
Authors
Publisher
Wiley